Format

Send to

Choose Destination
Rev Med Inst Mex Seguro Soc. 2019 Jul 31;57(2):65-73.

Piperacillin/tazobactam plus amikacin vs. piperacilin/tazobactam: treatment for children with febrile neutropenia

[Article in Spanish; Abstract available in Spanish from the publisher]

Author information

1
Instituto Mexicano del Seguro Social, Coordinación de Investigación en Salud, Unidad de Investigación en Epidemiología Hospitalaria. Ciudad de México, México

Abstract

in English, Spanish

Background:

Pediatric patients with febrile neutropenia usually receive a combination of broad spectrum antimicrobials. Treatment without aminoglycoside seems to have advantages.

Objective:

To compare the efficacy of piperacillin/tazobactam plus amikacin versus piperacillin/tazobactam.

Methods:

Randomized, open label, controlled clinical trial. Sample size for an efficacy of 55%, and delta of 25%; 80 episodes were required for each group. Selection criteria were patients with febrile neutropenia, candidates to receive parenteral antimicrobial treatment; they were randomized to one of two groups, piperacillin/tazobactam plus amikacin (Group A), or piperacillin/tazobactam (Group B). The outcomes were failure, adverse events and death. Mantel-Haenszel chi squaretest and exact Fisher test were used. Reduction of relative and absolute risk (RRR and ARR), 95% confidence intervals (CI 95%) and number needed to treat (NNT) were calculated.

Results:

88 Episodes were analyzed in group A and 76 in group B. There was no statistical difference in general characteristics of patients or type of infections. There was not significant statistical difference in: failure 31.8% group A, 30.2% group B (RR 1.05, CI 95% 0.66-1.66, p = 0.86), or adverse events (one in each group). The RRR was 1.5%, and ARR 2%, with a NNT of 67.

Conclusion:

Piperacillin/tazobactam without amikacin was as effective as combination therapy in pediatric patients with febrile neutropenia.

KEYWORDS:

Neoplasms; Febrile Neutropenia; Piperacillin; Tazobactam; Amikacin

PMID:
31617992

Supplemental Content

Loading ...
Support Center